What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population

View Full Paper

Ask AI

Bookmark

Authors

EZEric J. Zhao FKFlorian Kuchenbauer YMYasser Abou Mourad

Discussion

Member takes

Overview

Observational analysis reveals blurred survival outcomes among FLT3-ITD mutations and stem cell transplant in AML patients, suggesting the need for refined prognostication.

Key Points

Overall survival was not significantly different in patients with intermediate and adverse risk categories, indicating potential limitations in risk assessment.
Median overall survival at 75 months in favorable risk category notably contrasts with 30 months and 27 months in intermediate and adverse risk, respectively.
Study applied randomized controlled trial methods to a real-world population, including 499 AML patients diagnosed from 2016 to 2023 with varied genetic backgrounds.
Findings highlight challenges in using existing risk stratification for patients undergoing stem cell transplant, calling for further investigation in adverse risk groups.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9ea https://doi.org/10.1182/blood-2025-5178

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population

View Full Paper

Ask AI

Bookmark

Authors

EZEric J. Zhao FKFlorian Kuchenbauer YMYasser Abou Mourad

Discussion

Member takes

Overview

Observational analysis reveals blurred survival outcomes among FLT3-ITD mutations and stem cell transplant in AML patients, suggesting the need for refined prognostication.

Key Points

Overall survival was not significantly different in patients with intermediate and adverse risk categories, indicating potential limitations in risk assessment.
Median overall survival at 75 months in favorable risk category notably contrasts with 30 months and 27 months in intermediate and adverse risk, respectively.
Study applied randomized controlled trial methods to a real-world population, including 499 AML patients diagnosed from 2016 to 2023 with varied genetic backgrounds.
Findings highlight challenges in using existing risk stratification for patients undergoing stem cell transplant, calling for further investigation in adverse risk groups.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9ea https://doi.org/10.1182/blood-2025-5178

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark